FEATURED

Ascites in Patients with Cancer

Up to 10 percent of ascites diagnoses are related to cancer.

Anti-PD-L1 Antibody and Triple-Negative Breast Cancer

Report from a phase 1 trial presented at the 2015 American Association for Cancer Research (AACR) annual meeting.

Genetic Mutations in mCRPC

A summary of sessions related to genetic mutations in metastatic castrate-resistant prostate cancer at the 2014 AACR annual meeting.

Sunitinib and Small-Cell Lung Cancer

A phase II trial shows promise for patients with extensive small cell lung cancer who currently have limited treatment options.

The Desire for Gene Testing

A survey of ethnically diverse women treated for breast cancer has identified a "complete failure" among health care professionals to address concerns about genetic risk.

Using herceptin-immobilized gold nanoparticles

Gold nanoparticles offer important new possibilities in cancer diagnosis and therapy.

Ipilimumab for High-Risk Melanoma

In patients with completely resected high-risk stage 3 melanoma, adjuvant ipilimumab significantly improved recurrence-free survival.

Drug Showcase: BLINCYTO (blinatumomab)

Indicated for B-cell precursor acute lymphoblastic lymphoma.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Viewpoints

Anti-PD-L1 Antibody Demonstrates Antitumor Activity in Triple-Negative Breast Cancer

Anti-PD-L1 Antibody Demonstrates Antitumor Activity in Triple-Negative Breast Cancer

Report from a phase 1 trial presented at the 2015 American Association for Cancer Research (AACR) annual meeting.

Sunitinib Showing Promise for Small-Cell Lung Cancer

Sunitinib Showing Promise for Small-Cell Lung Cancer

A phase II trial shows promise for patients with extensive small cell lung cancer who currently have limited treatment options.

Feature Articles

Malignant Ascites: Diagnosis and Management

Malignant Ascites: Diagnosis and Management

Up to 10 percent of ascites diagnoses are related to cancer.

Role of Genetic Mutations in Metastatic Castrate-Resistant Prostate Cancer Treatment

Role of Genetic Mutations in Metastatic Castrate-Resistant Prostate Cancer Treatment

A summary of sessions related to genetic mutations in metastatic castrate-resistant prostate cancer at the 2014 AACR annual meeting.

Featured Videos

March/April Digital Issue

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs